PEP-Therapy is a Paris-based biotechnology company developing next-generation therapies using our intracellular drug delivery shuttle. Our technology platform enables us to address the previously undruggable intracellular space with multiple payloads such as peptides, proteins, antibodies, and nucleic acids. As a demonstrator, PEP-010, our first drug candidate developed in oncology, is a pro-apoptotic peptide which has shown anti-tumoral activity and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. The trial is conducted in partnership with two leading European cancer centers, Institut Curie and Gustave Roussy. PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.
Looking for a particular PEP-Therapy employee's phone or email?
PEP-Therapy Questions
The PEP-Therapy annual revenue was $1 million in 2026.
Antoine Prestat is the Co-founder and CEO of PEP-Therapy.
7 people are employed at PEP-Therapy.
PEP-Therapy is based in Paris, Île-de-France.
The NAICS codes for PEP-Therapy are [54, 541, 541713, 5417, 54171].
The SIC codes for PEP-Therapy are [873, 87].
Top PEP-Therapy Employees
-
Antoine Prestat
Co-founder and CEO at PEP-Therapy
Île-de-France, France12 -
2
-
Piedad Dickinson
Designer at PEP-Therapy
New York, United States1
Related Companies
